ClinicalTrials.gg

Program

rademikibart

Also written as “CBP-201”, “Rademikibart in prefilled syringe” and “Rademikibart”.

Its studies are mostly in Dermatitis, Atopic · Asthma · Pulmonary Disease, Chronic Obstructive · Nasal Polyps, led by Connect Biopharm.

Furthest: phase 3, since Nov 6, 202210 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Connect Biopharm102 open or runningphase 3since Nov 6, 2022Jun 15, 2020Dec 2026phase 2 · NCT07705737

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 15, 2020First study: phase 2 study in Moderate-to-severe Atopic DermatitisFirst studyNCT04444752 · 226 enrolled · United States, Australia, China and more
  2. Feb 24, 20212 phase 2 studiesNCT04783389, NCT04773678
  3. Aug 13, 2021Phase 2 study in Moderate-to-severe Atopic DermatitisNCT05017480 · 330 enrolled · China
  4. Nov 6, 2022Phase 3 study in Dermatitis, AtopicNCT05614817
  5. Jun 4, 2023Phase 1 study in Healthy Adult SubjectsNCT05917782 · 324 enrolled · China
  6. Jun 5, 2023Phase 2 study in Dermatitis, AtopicNCT05905133 · 360 enrolled · China
  7. Apr 3, 20252 phase 2 studiesNCT06940154, NCT06940141
  8. Jul 10, 2026Phase 2 study in AsthmaNCT07705737 · 40 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in AsthmaNCT07705737

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07705737Asthma · United States2RecruitingDec 202640
NCT06940154Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more2CompletedJul 30, 2026159
NCT06940141Asthma · United States, Argentina, Australia and more2CompletedJul 17, 2026160
NCT05905133Dermatitis, Atopic · China2Active, not recruitingJun 30, 2024360
NCT05917782Healthy Adult Subjects · China1CompletedOct 6, 2023324
NCT05614817Dermatitis, Atopic3WithdrawnAug 20240
NCT05017480Moderate-to-severe Atopic Dermatitis · China2CompletedDec 1, 2022330
NCT04783389Chronic Rhinosinusitis With Nasal Polyps · United States, China, Poland and more2TerminatedApr 15, 202240
NCT04773678Moderate to Severe Persistent Asthma · United States, China, Hungary and more2CompletedAug 5, 2023322
NCT04444752Moderate-to-severe Atopic Dermatitis · United States, Australia, China and more2CompletedJul 28, 2021226

How it is read

Names in the registry

  • “CBP-201”, 6 entries
  • “Rademikibart in prefilled syringe”, 2 entries
  • “Rademikibart”, 1 entry
  • “Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)”, 1 entry
  • “Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)”, 1 entry

Codes read as this program: CBP201.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.